Literature DB >> 29296770

Osteonecrosis of the femoral head in sickle cell disease: prevalence, comorbidities, and surgical outcomes in California.

Oyebimpe Adesina1, Ann Brunson2, Theresa H M Keegan2, Ted Wun2.   

Abstract

Osteonecrosis of the femoral head (ONFH) is a prevalent complication of sickle cell disease (SCD) that has not been well described in population-based cohort studies. Using California's Office of Statewide Planning and Development discharge databases (1991-2013), we estimated the cumulative incidence of ONFH after accounting for the competing risk of death and used a multivariable Cox proportional hazards regression to identify factors associated with ONFH diagnosis. We also calculated rates of readmissions to the hospital or emergency department within 30 to 90 days of hip replacement surgery. Of the 6237 patients in our SCD cohort, 22% (n = 1356) developed ONFH at a median age of 27 years, and 23% (n = 308) of the patients with ONFH underwent hip replacement surgery at a median age of 36 years. The cumulative incidence of ONFH to age 30 years was higher among SCD patients with more severe disease (24%; vs 8% in less severe) and those with antecedent acute chest syndrome (ACS) (18%; vs 8% without prior history of ACS). From 2003 to 2013, SCD patients with more severe disease (hazard ratio [HR], 2.77; 95% confidence interval [CI], 2.38-3.23) or with antecedent ACS (HR, 1.61; CI, 1.35-1.91) were more likely to develop ONFH. Twenty-seven percent of post-hip surgery patients were readmitted within 30 days, mostly for painful vaso-occlusive crises. ONFH is a common SCD complication that increases with age; ongoing studies into prevention and effective nonsurgical interventions for SCD-induced osteonecrosis must remain a high research priority.

Entities:  

Year:  2017        PMID: 29296770      PMCID: PMC5728545          DOI: 10.1182/bloodadvances.2017005256

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  60 in total

1.  Sickle-cell disease in California: a population-based description of emergency department utilization.

Authors:  Julie A Wolfson; Sheree M Schrager; Thomas D Coates; Michele D Kipke
Journal:  Pediatr Blood Cancer       Date:  2010-11-24       Impact factor: 3.167

2.  Modern total hip arthroplasty in patients younger than 21 years.

Authors:  Atul F Kamath; Neil P Sheth; Harish H Hosalkar; Oladapo M Babatunde; Gwo-Chin Lee; Charles L Nelson
Journal:  J Arthroplasty       Date:  2011-07-01       Impact factor: 4.757

3.  Hip arthroplasty in patients with sickle-cell haemoglobinopathy.

Authors:  M T Acurio; R J Friedman
Journal:  J Bone Joint Surg Br       Date:  1992-05

4.  Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study.

Authors:  Jane S Hankins; Russell E Ware; Zora R Rogers; Lynn W Wynn; Peter A Lane; J Paul Scott; Winfred C Wang
Journal:  Blood       Date:  2005-10-01       Impact factor: 22.113

5.  Physical therapy alone compared with core decompression and physical therapy for femoral head osteonecrosis in sickle cell disease. Results of a multicenter study at a mean of three years after treatment.

Authors:  Lynne D Neumayr; Christine Aguilar; Ann N Earles; Harry E Jergesen; Charles M Haberkern; Bamidele F Kammen; Paul A Nancarrow; Eric Padua; Meredith Milet; Bernard N Stulberg; Roger A Williams; Eugene P Orringer; Nora Graber; Shanda M Robertson; Elliott P Vichinsky
Journal:  J Bone Joint Surg Am       Date:  2006-12       Impact factor: 5.284

Review 6.  An update on the recent literature on sickle cell bone disease.

Authors:  Ifeyinwa Osunkwo
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2013-12       Impact factor: 3.243

Review 7.  Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes.

Authors:  Gregory J Kato; Mark T Gladwin; Martin H Steinberg
Journal:  Blood Rev       Date:  2006-11-07       Impact factor: 8.250

8.  Defining Sickle Cell Disease Mortality Using a Population-Based Surveillance System, 2004 through 2008.

Authors:  Susan T Paulukonis; James R Eckman; Angela B Snyder; Ward Hagar; Lisa B Feuchtbaum; Mei Zhou; Althea M Grant; Mary M Hulihan
Journal:  Public Health Rep       Date:  2016 Mar-Apr       Impact factor: 2.792

9.  Total THA in adult osteonecrosis related to sickle cell disease.

Authors:  Philippe Hernigou; Sebastien Zilber; Paolo Filippini; Gilles Mathieu; Alexandre Poignard; Frederic Galacteros
Journal:  Clin Orthop Relat Res       Date:  2008-01-10       Impact factor: 4.176

10.  The Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) study: a randomised, controlled, multicentre clinical trial.

Authors:  Jo Howard; Moira Malfroy; Charlotte Llewelyn; Louise Choo; Renate Hodge; Tony Johnson; Shilpi Purohit; David C Rees; Louise Tillyer; Isabeau Walker; Karin Fijnvandraat; Melanie Kirby-Allen; Eldon Spackman; Sally C Davies; Lorna M Williamson
Journal:  Lancet       Date:  2013-01-23       Impact factor: 79.321

View more
  26 in total

1.  CE: Understanding the Complications of Sickle Cell Disease.

Authors:  Paula Tanabe; Regena Spratling; Dana Smith; Peyton Grissom; Mary Hulihan
Journal:  Am J Nurs       Date:  2019-06       Impact factor: 2.220

2.  Circulating microRNA signature of steroid-induced osteonecrosis of the femoral head.

Authors:  Zheng Li; Chao Jiang; Xingye Li; William K K Wu; Xi Chen; Shibai Zhu; Chanhua Ye; Matthew T V Chan; Wenwei Qian
Journal:  Cell Prolif       Date:  2017-12-04       Impact factor: 6.831

3.  Increased risk of leukemia among sickle cell disease patients in California.

Authors:  Ann Brunson; Theresa H M Keegan; Heejung Bang; Anjlee Mahajan; Susan Paulukonis; Ted Wun
Journal:  Blood       Date:  2017-08-22       Impact factor: 22.113

4.  Bleeding in patients with sickle cell disease: a population-based study.

Authors:  Nisha Hariharan; Ann Brunson; Anjlee Mahajan; Theresa H M Keegan; Ted Wun
Journal:  Blood Adv       Date:  2020-03-10

Review 5.  Emerging roles of MicroRNAs in osteonecrosis of the femoral head.

Authors:  Zheng Li; Bo Yang; Xisheng Weng; Gary Tse; Matthew T V Chan; William Ka Kei Wu
Journal:  Cell Prolif       Date:  2017-11-12       Impact factor: 6.831

6.  Optimal disease management and health monitoring in adults with sickle cell disease.

Authors:  Jo Howard; Swee Lay Thein
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 7.  Osteonecrosis in sickle cell disease: an update on risk factors, diagnosis, and management.

Authors:  Oyebimpe O Adesina; Lynne D Neumayr
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

8.  High incidence of venous thromboembolism recurrence in patients with sickle cell disease.

Authors:  Ann Brunson; Theresa Keegan; Anjlee Mahajan; Richard White; Ted Wun
Journal:  Am J Hematol       Date:  2019-06-12       Impact factor: 10.047

9.  Osteonecrosis in sickle cell disease patients from Bahia, Brazil: a cross-sectional study.

Authors:  Gildasio Daltro; Bruno Adelmo Franco; Thiago Batista Faleiro; Davi Araujo Veiga Rosário; Paula Braga Daltro; Vitor Fortuna
Journal:  Int Orthop       Date:  2018-03-26       Impact factor: 3.075

10.  Cancer specific survival in patients with sickle cell disease.

Authors:  Ann Brunson; Theresa H M Keegan; Anjlee Mahajan; Susan Paulukonis; Ted Wun
Journal:  Br J Haematol       Date:  2018-11-22       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.